Yang Zhengjie, Guo Qianping, Cai Yan, Zhu Xuesong, Zhu Caihong, Li Yuling, Li Bin
Department of Orthopedic Surgery, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, Suzhou, China.
Department of Orthopedic Surgery, Wuxi No.2 People's Hospital, Nanjing Medical University, Wuxi, China.
J Orthop Translat. 2019 Dec 6;21:57-65. doi: 10.1016/j.jot.2019.11.001. eCollection 2020 Mar.
The survival rate of osteosarcoma therapy still lags behind overall cancer therapies due to the intrinsic or acquired drug resistance. Developing novel drug delivery systems that may overcome drug resistance would greatly facilitate osteosarcoma therapy.
Poly(ethylene glycol) (PEG)-sheddable reduction-sensitive polyurethane (SS-PU-SS-PEG) was synthesized using a disulfide-containing polycaprolactone diol as the hydrophobic block and a cystamine-functionalized PEG as the hydrophilic block. SS-PU-SS-PEG micelles were then prepared to load the anti-tumor drug Doxorubicin (DOX) in order to achieve triggered intracellular drug delivery to improve the efficacy of osteosarcoma therapy.
When DOX was used as a model drug, the drug-loaded SS-PU-SS-PEG micelles were about 82∼94 nm in diameter and exhibited good stability in phosphate buffer saline (PBS). The micelles could release about 80% DOX in a quantitative fashion within 5 hours under a reductive environment. The intracellular drug release of DOX-loaded SS-PU-SS-PEG micelles increased upon incubation with Saos-2 cells in vitro. The micelles had good biocompatibility. In vitro, DOX-loaded SS-PU-SS-PEG micelles showed significant antitumor activity toward Saos-2 cells, which was close to that of free DOX. In vivo, DOX-loaded SS-PU-SS-PEG micelles exhibited better antitumor activity than free DOX.
Findings from this study suggest that the SS-PU-SS-PEG micelles could achieve well-controlled triggered drug release in a reduction environment and could therefore improve the antitumor efficacy of osteosarcoma therapies.
In this study we developed PEG-sheddable reduction-sensitive polyurethane micelles (SS-PU-SS-PEG), which were able to achieve well-controlled triggered release of anti-tumor drug Doxorubicin (DOX) in an intracellular reduction environment. DOX-loaded SS-PU-SS-PEG micelles markedly improved the antitumor efficacy in a Saos-2 cells-bearing xenograft tumor model. Therefore, such micelles might be used as a novel drug delivery system for osteosarcoma treatment.
由于内在或获得性耐药性,骨肉瘤治疗的生存率仍落后于整体癌症治疗。开发可能克服耐药性的新型药物递送系统将极大地促进骨肉瘤治疗。
以含二硫键的聚己内酯二醇为疏水嵌段,胱胺功能化聚乙二醇为亲水嵌段,合成了聚乙二醇(PEG)可脱落的还原敏感型聚氨酯(SS-PU-SS-PEG)。然后制备SS-PU-SS-PEG胶束以负载抗肿瘤药物阿霉素(DOX),以实现触发细胞内药物递送,提高骨肉瘤治疗效果。
以DOX为模型药物时,载药的SS-PU-SS-PEG胶束直径约为82~94nm,在磷酸盐缓冲盐水(PBS)中表现出良好的稳定性。在还原环境下,胶束可在5小时内定量释放约80%的DOX。载DOX的SS-PU-SS-PEG胶束与Saos-2细胞体外孵育后,细胞内药物释放增加。胶束具有良好的生物相容性。在体外,载DOX的SS-PU-SS-PEG胶束对Saos-2细胞显示出显著的抗肿瘤活性,与游离DOX接近。在体内,载DOX的SS-PU-SS-PEG胶束表现出比游离DOX更好的抗肿瘤活性。
本研究结果表明,SS-PU-SS-PEG胶束可在还原环境中实现可控的触发药物释放,从而提高骨肉瘤治疗的抗肿瘤疗效。
在本研究中,我们开发了PEG可脱落的还原敏感型聚氨酯胶束(SS-PU-SS-PEG),其能够在细胞内还原环境中实现抗肿瘤药物阿霉素(DOX)的可控触发释放。载DOX的SS-PU-SS-PEG胶束在携带Saos-2细胞的异种移植肿瘤模型中显著提高了抗肿瘤疗效。因此,这种胶束可能用作骨肉瘤治疗的新型药物递送系统。